UNSPSC 51401905: Panadiplon

This classification denotes an anxiolytic with the molecular formula C18H17N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V4PW0S7ZP7, chemically known as 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-isopropylimidazo(1,5-a)quinoxalin-4(5h)-one but generally known as panadiplon, which bears US NIH Compound Identifier 3033821. European Medicines Agency schedules Panadiplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09600MIG. The term PANADIPLON is an International Non-Proprietary Name.

UNSPSC 51401905 Panadiplon (Commodity) represents pharmaceutical procurement by state and local health agencies, though recent state and local opportunities show the code capturing a broader portfolio of pharmaceutical and over-the-counter product sourcing than the commodity name alone suggests. State and local governments are acquiring generic multi-source pharmaceuticals, naloxone and drug deactivation systems, and OTC products through competitive bid processes and cooperative purchasing vehicles. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission are recent active buyers; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates procurement across multiple participating state and local jurisdictions including Oregon.

Recent activity spans Florida, Texas, and Minnesota-anchored cooperative arrangements. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to its Community Health Building in Sanford, with a July 26, 2023 response deadline and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program supporting direct contracting between state agencies and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating jurisdictions, with proposals due March 26, 2026, requiring vendors to work through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and comply with cGMP, DSCSA, and FDA requirements.